Press Release
19/09/2022

SpectraCure's new treatment system has been approved in the UK for use in clinical trials

SpectraCure's new generation of treatment systems has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) for use in the ongoing clinical trial for the treatment of relapsing prostate cancer.

The new treatment system has already been approved by the authorities in Canada and the USA, which means that the system is now approved for use in the ongoing clinical trial in all countries where SpectraCure's trial is underway. The new system is functionally equivalent to the previous one in compliance with regulatory requirements. This is relevant because the new system will be used in the same trial. The new system is smaller, easier to use and cheaper to manufacture than the previous one. SpectraCure's production facilities in Lund are already manufacturing several units for use in clinical trials.

> "*The new system now completely replaces the previous one in the ongoing clinical trial. The approved system is much better adapted from a business standpoint, as it is both easier to use and cheaper to manufacture*", says Johan Folkunger, SpectraCure's CEO.

For further information:
Johan Folkunger, CEO
Email: jf@spectracure.com
Website: www.spectracure.com

SpectraCure is developing a treatment system for the elimination of internal solid cancer tumors. We are initially focusing on relapsing cancer in the prostate, with the hope of being able to treat other cancers such as primary prostate cancer, breast cancer, pancreatic cancer, and head and neck cancer in the future. The approach is based on a proprietary and patented treatment system consisting of hardware, a laser device, which performs PDT treatment and treats the prostate itself, combined with software, the patented IDOSE® dosage planning platform. The method allows the laser light dose to be controlled so that the tumour is exposed to an optimal dose to achieve sufficient treatment effect. The treatment system has the potential to make interstitial PDT treatment accurate, precise and safe for every patient. The goal is that, in addition to being tumour-free, the patients should be able to maintain their quality of life, with limited side effects. We are conducting clinical trials as an important part of the ongoing development of the company's treatment system.

The company is listed in the Premier segment on Nasdaq First North Growth Market with G&W Fondkommission as Certified Adviser, ca@gwkapital.se, tel +468-503 00 050, and trades by SPEC ticker symbol.